Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Lantheus Holdings, Inc. before investing.

In this article, we go over a few key elements for understanding Lantheus Holdings, Inc.’s stock price such as:

• Lantheus Holdings, Inc.’s current stock price and volume
• Why Lantheus Holdings, Inc.’s stock price changed recently
• Upgrades and downgrades for LNTH from analysts
• LNTH’s stock price momentum as measured by its relative strength

About Lantheus Holdings, Inc. (LNTH)

Before we jump into Lantheus Holdings, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer’s disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Want to learn more about Lantheus Holdings, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Lantheus Holdings, Inc..

Lantheus Holdings, Inc.’s Stock Price as of Market Close

As of May 07, 2025, 12:31 PM, CST, Lantheus Holdings, Inc.’s stock price was $81.420.

Lantheus Holdings, Inc. is down 22.34% from its previous closing price of $104.840.

During the last market session, Lantheus Holdings, Inc.’s stock traded between $80.000 and $89.900. Currently, there are approximately 69.22 million shares outstanding for Lantheus Holdings, Inc..

Lantheus Holdings, Inc.’s price-earnings (P/E) ratio is currently at 24.0, which is low compared to the Health Care Equipment & Supplies industry median of 31.5. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Lantheus Holdings, Inc. Stock Price History

Lantheus Holdings, Inc.’s (LNTH) price is currently down 21.97% so far this month.

During the month of May, Lantheus Holdings, Inc.’s stock price has reached a high of $108.910 and a low of $80.000.

Over the last year, Lantheus Holdings, Inc. has hit prices as high as $126.890 and as low as $74.280. Year to date, Lantheus Holdings, Inc.’s stock is down 8.99%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Lantheus Holdings, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 06, 2025, there was 1 analyst who downgraded Lantheus Holdings, Inc.’s stock and 2 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Lantheus Holdings, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Lantheus Holdings, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Lantheus Holdings, Inc.’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Lantheus Holdings, Inc. (LNTH) by visiting AAII Stock Evaluator.

Relative Price Strength of Lantheus Holdings, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 06, 2025, Lantheus Holdings, Inc. has a weighted four-quarter relative price strength of 11.64%, which translates to a Momentum Score of 87 and is considered to be Very Strong.

Want to learn more about how Lantheus Holdings, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Lantheus Holdings, Inc. Stock Price: Bottom Line

As of May 7, 2025, Lantheus Holdings, Inc.’s stock price is $81.420, which is down 22.34% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Lantheus Holdings, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.